Universal Access & Affordable Medicines Forum of the European Public Health Alliance, organized by the European Public Health Alliance (epha) under the auspices of the Belgian Ministry of Health 21.11. 2017
By Lauren Tuchman, ANME
This was a well-attended event filled with varying participants from a multitude of organizations. The atmosphere was lively, questions were raised, and the panels throughout the days were diverse, interactive, and the members actively engaged with the attendees. In the opening remarks from Yannis Nastis, (Policy Manager, Universal Access and Affordable Medicines, European Public Health Alliance [EPHA]), one point was made that was reiterated by many of the panelists of the day: Access to medicine is no longer just a topic and concern for the Ministry of Health; it is important that the Ministry of Finance become more involved and address public concerns.
Report from the 9th World Health Summit 2017 in Berlin, 15th-17th of October
A political update: What’s going on in mainstream Health Policies?
By Nora Laubstein
About 2000 participants attended the three day World Health Summit (WHS) in Berlin under the patronage of Angela Merkel, Emmanuel Macron and German Health Minister Herman Gröhe. The presidency for this year was held by Helene Boisjoly, University of Montreal and WHS-founding President Detlev Ganten, Charite-University. Both are partners of the M8-Alliance, a 2009 founded network of 20 global Academic Health Centers, Universities and National Academies.
Homeopathic products and practices: assessing the evidence and ensuring consistency in regulating medical claims in the EU” - full report under: http:/www.easac.eu/↗
Please read here the statements of the Homeopathy Reseach Institute/ HRI: https://www.hri-research.org/↗
Bundesverband Pharmazeutischer Industrie/BPI: http://www.bpi.de/↗
and our partner ECHAMP:
ECHAMP is the European Coalition on Homeopathic & Anthroposophic Medicinal Products. It works to develop the industry for these medicinal products so as to ensure availability of both medicines for self-medication and medicines recommended by prescribers. It advocates in favour of an appropriate regulatory environment for these products in the EU.
Beekeepers, scientists, policy-makers and other relevant parties are to set up a European bee partnership that could transform the way bee health is assessed in the EU – Brussels-2017-26th of June.
Comment by Dr. Friedrich Hainbuch, ANME:
As a participant of group TWO I can only speak for this group. In principle, I can say that many delegates and representatives of various EU institutions were involved. Also many representatives of the agrochemical groups and a few scientists attended.
I missed critical and rather skeptical scientists, such as Thomas Seeley, Randolf Menzel, Prof. Tautz, Dr. Safer, Dr. Alexandra Henrion-Claude or G.-E. SérTalini.
In this spectrum research and industrial interests were located, on one side:
The first EU-wide field-study which documents bee-damaging by neonicotinoids, "The degradation rate of thiamethoxam in European field studies"↗ and on the other side a contradictory study, commissioned by BAYER industries, which showed that Imidacloprid and other neonicotinoids were absolutely non-toxic for bees.
Press release, The Hague / Munich, 29 June 2017
On a proposal of the European Patent Office its Administrative Council took a decision to amend the relevant Regulations in order to exclude from patentability plants and animals exclusively obtained by an essentially biological breeding process.
Press release of 16 June 2017
The Swiss Federal Government announces that specific medical services using complementary med- icine are to be covered by mandatory health insurance (basic insurance). The Swiss Umbrella Association for Complementary Medicine and the Union of Associations of Swiss Physicians for Comple-mentary Medicine welcome this decision. It implements one of the key demands of the constitutional referendum held on 17 May 2009. With this decision, the Swiss Federal Council is acknowledging that complementary medicine in Switzerland meets statutory regulations when it comes to effectiveness, guaranteeing high quality and safety.
In 2016, the European Commission’s EU Health Award recognises and rewards the efforts and achievements of European NGOs towards reducing the threat to human health from antimicrobial resistance. Antimicrobial Resistance (AMR) is one of the most challenging threats to human health. Each year, drug resistant infections result in an estimated 25,000 deaths and 1.5 billion euros in healthcare costs and productivity losses in the EU.
United Nations Secretary-General’s High-Level Panel on Access to Medicines calls for New Deal to close the Health Innovation and Access Gap
Whether it’s the rising price of the EpiPen, or new outbreaks of diseases, like Ebola, Zika and yellow fever, the rising costs of health technologies and the lack of new tools to tackle health problems, like antimicrobial resistance, is a problem in rich and poor countries alike.
According to a High-Level Panel convened to advise the UN Secretary-General on improving access to medicines, the world must take bold new approaches to both health technology innovation and ensuring access so that all people can benefit from the medical advances that have dramatically improved the lives of millions around the world in the last century.